Related references
Note: Only part of the references are listed.Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy
Anna Greco et al.
CLINICAL GENETICS (2020)
Longitudinal measures of RNA expression and disease activity in FSHD muscle biopsies
Chao-Jen Wong et al.
HUMAN MOLECULAR GENETICS (2020)
Magnetic resonance imaging correlates with electrical impedance myography in facioscapulohumeral muscular dystrophy
Johanna Hamel et al.
MUSCLE & NERVE (2020)
Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy
Angela Lek et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies
Christian Leborgne et al.
NATURE MEDICINE (2020)
Homozygous nonsense variant in LRIF1 associated with facioscapulohumeral muscular dystrophy
Kohei Hamanaka et al.
NEUROLOGY (2020)
p38 alpha Regulates Expression of DUX4 in a Model of Facioscapulohumeral Muscular Dystrophy
L. Alejandro Rojas et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)
Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy
Kenji Rowel Q. Lim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level
Christopher R. S. Banerji et al.
HUMAN MOLECULAR GENETICS (2019)
Relationship between muscle inflammation and fat replacement assessed by MRI in facioscapulohumeral muscular dystrophy
Julia R. Dahlqvist et al.
JOURNAL OF NEUROLOGY (2019)
The Genetics and Epigenetics of Facioscapulohumeral Muscular Dystrophy
Charis L. Himeda et al.
Annual Review of Genomics and Human Genetics (2019)
Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy
Jonathan Oliva et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Preliminary Evidences of Safety and Efficacy of Flavonoids- and Omega 3-Based Compound for Muscular Dystrophies Treatment: A Randomized Double-Blind Placebo Controlled Pilot Clinical Trial
Clementina Sitzia et al.
FRONTIERS IN NEUROLOGY (2019)
Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study
Samantha LoRusso et al.
BMC NEUROLOGY (2019)
A novel P300 inhibitor reverses DUX4-mediated global histone H3 hyperacetylation, target gene expression, and cell death
Darko Bosnakovski et al.
SCIENCE ADVANCES (2019)
DUX4-induced bidirectional HSATII satellite repeat transcripts form intranuclear double-stranded RNA foci in human cell models of FSHD
Sean C. Shadle et al.
HUMAN MOLECULAR GENETICS (2019)
Intronic SMCHD1 variants in FSHD: testing the potential for CRISPR-Cas9 genome editing
Remko Goossens et al.
JOURNAL OF MEDICAL GENETICS (2019)
Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease
R. S. Pearsall et al.
SCIENTIFIC REPORTS (2019)
MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD
Leo H. Wang et al.
HUMAN MOLECULAR GENETICS (2019)
Identification of the hyaluronic acid pathway as a therapeutic target for facioscapulohumeral muscular dystrophy
Alec M. DeSimone et al.
SCIENCE ADVANCES (2019)
A 22-year follow-up reveals a variable disease severity in early-onset facioscapulohumeral dystrophy
Rianne J. M. Goselink et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2018)
ELECTRICAL IMPEDANCE MYOGRAPHY IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY: A 1-YEAR FOLLOW-UP STUDY
Karlien Mul et al.
MUSCLE & NERVE (2018)
LOCALLY ACTING ACE-083 INCREASES MUSCLE VOLUME IN HEALTHY VOLUNTEERS
Chad E. Glasser et al.
MUSCLE & NERVE (2018)
Facioscapulohumeral muscular dystrophy functional composite outcome measure
Katy Eichinger et al.
MUSCLE & NERVE (2018)
Functional domains of the FSHD-associated DUX4 protein
Hiroaki Mitsuhashi et al.
BIOLOGY OPEN (2018)
Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD
Lindsay M. Wallace et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2018)
A patient-derived iPSC model revealed oxidative stress increases facioscapulohumeral muscular dystrophy-causative DUX4
Mitsuru Sasaki-Honda et al.
HUMAN MOLECULAR GENETICS (2018)
Quantitative muscle MRI and ultrasound for facioscapulohumeral muscular dystrophy: complementary imaging biomarkers
Karlien Mul et al.
JOURNAL OF NEUROLOGY (2018)
Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments
Johanna Hamel et al.
NEUROTHERAPEUTICS (2018)
AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD
Carlee R. Giesige et al.
JCI INSIGHT (2018)
A Pediatric Review of Facioscapulohumeral Muscular Dystrophy
Jean K. Mah et al.
JOURNAL OF PEDIATRIC NEUROLOGY (2018)
International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine
Richard B. Kreider et al.
JOURNAL OF THE INTERNATIONAL SOCIETY OF SPORTS NUTRITION (2017)
DUX-family transcription factors regulate zygotic genome activation in placental mammals
Alberto De Iaco et al.
NATURE GENETICS (2017)
Conserved roles of mouse DUX and human DUX4 in activating cleavage-stage genes and MERVL/HERVL retrotransposons
Peter G. Hendrickson et al.
NATURE GENETICS (2017)
Conservation and innovation in the DUX4-family gene network
Jennifer L. Whiddon et al.
NATURE GENETICS (2017)
Results of a Phase 1b/2 Study of ATYR1940 in adolescents and young adults with early onset facioscapulohumeral muscular dystrophy (FSHD) (ATYR1940-C-003)
G. Walker et al.
NEUROMUSCULAR DISORDERS (2017)
Human growth hormone stabilizes walking and improves strength in a patient with dominantly inherited calpainopathy
Kira Philipsen Prahm et al.
NEUROMUSCULAR DISORDERS (2017)
DUX4-induced dsRNA and MYC mRNA stabilization activate apoptotic pathways in human cell models of facioscapulohumeral dystrophy
Sean C. Shadle et al.
PLOS GENETICS (2017)
Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD)
Eugenie Ansseau et al.
GENES (2017)
BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells
Amy E. Campbell et al.
SKELETAL MUSCLE (2017)
Facioscapulohumeral Muscular Dystrophy
Alec M. DeSimone et al.
COMPREHENSIVE PHYSIOLOGY (2017)
Mutations in DNMT3B Modify Epigenetic Repression of the D4Z4 Repeat and the Penetrance of Facioscapulohumeral Dystrophy
Marlinde L. van den Boogaard et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2016)
Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy
Jerry R. Mendell et al.
ANNALS OF NEUROLOGY (2016)
Antisense targeting of 3′ end elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach
Anne-Charlotte Marsollier et al.
HUMAN MOLECULAR GENETICS (2016)
DUX4 induces a transcriptome more characteristic of a less-differentiated cell state and inhibits myogenesis
Paul Knopp et al.
JOURNAL OF CELL SCIENCE (2016)
CRISPR/dCas9-mediated Transcriptional Inhibition Ameliorates the Epigenetic Dysregulation at D4Z4 and Represses DUX4-fl in FSH Muscular Dystrophy
Charis L. Himeda et al.
MOLECULAR THERAPY (2016)
Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics
Jennifer C. J. Chen et al.
MOLECULAR THERAPY (2016)
ELECTRICAL IMPEDANCE MYOGRAPHY IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
Jeffrey M. Statland et al.
MUSCLE & NERVE (2016)
A cross sectional study of two independent cohorts identifies serum biomarkers for facioscapulohumeral muscular dystrophy (FSHD)
Lisa M. Petek et al.
NEUROMUSCULAR DISORDERS (2016)
DUX4 recruits p300/CBP through its C-terminus and induces global H3K27 acetylation changes
Si Ho Choi et al.
NUCLEIC ACIDS RESEARCH (2016)
Brugia malayi Asparaginyl - tRNA Synthetase Stimulates Endothelial Cell Proliferation, Vasodilation and Angiogenesis
Jeeva D. Jothi et al.
PLOS ONE (2016)
Scalpel or Straitjacket: CRISPR/Cas9 Approaches for Muscular Dystrophies
Charis L. Himeda et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Homologous Transcription Factors DUX4 and DUX4c Associate with Cytoplasmic Proteins during Muscle Differentiation
Eugenie Ansseau et al.
PLOS ONE (2016)
Corticosteroids for the treatment of Duchenne muscular dystrophy
Emma Matthews et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2016)
Effects of vitamin C, vitamin E, zinc gluconate, and selenomethionine supplementation on muscle function and oxidative stress biomarkers in patients with facioscapulohumeral dystrophy: A double-blind randomized controlled clinical trial
Emilie Passerieux et al.
FREE RADICAL BIOLOGY AND MEDICINE (2015)
Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways
Amanda M. Rickard et al.
HUMAN MOLECULAR GENETICS (2015)
Testosterone Treatment of Pubertal Delay in Duchenne Muscular Dystrophy
Claire L. Wood et al.
NEUROPEDIATRICS (2015)
Emerging preclinical animal models for FSHD
Angela Lek et al.
TRENDS IN MOLECULAR MEDICINE (2015)
A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy
Qing Feng et al.
ELIFE (2015)
Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial
Clemens Becker et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
HIF-1α pathway: role, regulation and intervention for cancer therapy
Georgina N. Masoud et al.
ACTA PHARMACEUTICA SINICA B (2015)
β-catenin is central to DUX4-driven network rewiring in facioscapulohumeral muscular dystrophy
Christopher R. S. Banerji et al.
JOURNAL OF THE ROYAL SOCIETY INTERFACE (2015)
Hyaluronan: Biosynthesis and signaling
Davide Vigetti et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2014)
An integrated approach in a case of facioscapulohumeral dystrophy
Stefano Pasotti et al.
BMC MUSCULOSKELETAL DISORDERS (2014)
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study
Thomas Voit et al.
LANCET NEUROLOGY (2014)
Population-based incidence and prevalence of facioscapulohumeral dystrophy
Johanna C. W. Deenen et al.
NEUROLOGY (2014)
Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity
F. Ann Ran et al.
CELL (2013)
Wnt/β-catenin signaling suppresses DUX4 expression and prevents apoptosis of FSHD muscle cells
Gregory J. Block et al.
HUMAN MOLECULAR GENETICS (2013)
Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders
Rosamund C. Smith et al.
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE (2013)
Facioscapulohumeral muscular dystrophy: consequences of chromatin relaxation
Silvere M. van der Maarel et al.
CURRENT OPINION IN NEUROLOGY (2012)
DUX4 Activates Germ line Genes, Retroelements, and Immune Mediators: Implications for Facioscapulohumeral Dystrophy
Linda N. Geng et al.
DEVELOPMENTAL CELL (2012)
Functional muscle impairment in facioscapulohumeral muscular dystrophy is correlated with oxidative stress and mitochondrial dysfunction
Ahmed Turki et al.
FREE RADICAL BIOLOGY AND MEDICINE (2012)
Patients with a phenotype consistent with facioscapulohumeral muscular dystrophy display genetic and epigenetic heterogeneity
Sabrina Sacconi et al.
JOURNAL OF MEDICAL GENETICS (2012)
RNA Interference Inhibits DUX4-induced Muscle Toxicity In Vivo: Implications for a Targeted FSHD Therapy
Lindsay M. Wallace et al.
MOLECULAR THERAPY (2012)
Patient-identified disease burden in facioscapulohumeral muscular dystrophy
Nicholas E. Johnson et al.
MUSCLE & NERVE (2012)
Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2
Richard J. L. F. Lemmers et al.
NATURE GENETICS (2012)
DUX4, a Candidate Gene for Facioscapulohumeral Muscular Dystrophy, Causes p53-Dependent Myopathy In Vivo
Lindsay M. Wallace et al.
ANNALS OF NEUROLOGY (2011)
Creatine for treating muscle disorders
Rudolf A. Kley et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2011)
Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors
Sylvie Boutin et al.
HUMAN GENE THERAPY (2010)
A p38MAPK/HIF-1 Pathway Initiated by UVB Irradiation Is Required to Induce Noxa and Apoptosis of Human Keratinocytes
Kris Nys et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Effect of creatine monohydrate in improving cellular energetics and muscle strength in ambulatory Duchenne muscular dystrophy patients: a randomized, placebo-controlled 31P MRS study
Bidisha Banerjee et al.
MAGNETIC RESONANCE IMAGING (2010)
A Unifying Genetic Model for Facioscapulohumeral Muscular Dystrophy
Richard J. L. F. Lemmers et al.
SCIENCE (2010)
Periodic Salbutamol in Facioscapulohumeral Muscular Dystrophy: A Randomized Controlled Trial
C. A. Payan et al.
ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION (2009)
Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population
Xin Ye et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Hematopoietic Protein Tyrosine Phosphatase Mediates β2-Adrenergic Receptor-Induced Regulation of p38 Mitogen-Activated Protein Kinase in B Lymphocytes
Jaclyn W. McAlees et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy
Kathryn R. Wagner et al.
ANNALS OF NEUROLOGY (2008)
Role of beta-adrenoceptor signaling in skeletal muscle: Implications for muscle wasting and disease
Gordon S. Lynch et al.
PHYSIOLOGICAL REVIEWS (2008)
The role of corticosteroids in muscular dystrophy: A critical appraisal
Corrado Angelini
MUSCLE & NERVE (2007)
Interaction between β-catenin and HIF-1 promotes cellular adaptation to hypoxia
Abderrahmane Kaidi et al.
NATURE CELL BIOLOGY (2007)
No effect of folic acid and methionine supplementation on D4Z4 methylation in patients with facioscapulohumeral muscular dystrophy
E. L. van der Kooi et al.
NEUROMUSCULAR DISORDERS (2006)
Severe phenotype in infantile facioscapulohumeral muscular dystrophy
Lars Klinge et al.
NEUROMUSCULAR DISORDERS (2006)
Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins
Yisrael Sidis et al.
ENDOCRINOLOGY (2006)
Dual regulation of c-Myc by p300 via acetylation-dependent control of Myc protein turnover and coactivation of Myc-induced transcription
F Faiola et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Signal pathway of hypoxia-inducible factor-1α phosphorylation and its interaction with von Hippel-Lindau tumor suppressor protein during ischemia in MiaPaCa-2 pancreatic cancer cells
SJ Kwon et al.
CLINICAL CANCER RESEARCH (2005)
β2-agonist administration reverses muscle wasting and improves muscle function in aged rats
JG Ryall et al.
JOURNAL OF PHYSIOLOGY-LONDON (2004)
Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD)
MMO Tonini et al.
NEUROMUSCULAR DISORDERS (2004)
Somatic mosaicism in FSHD often goes undetected
RJLF Lemmers et al.
ANNALS OF NEUROLOGY (2004)
Regulation of muscle mass by myostatin
SJ Lee
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY (2004)
Creatine monohydrate in muscular dystrophies:: A double-blind, placebo-controlled clinical study
MC Walter et al.
NEUROLOGY (2000)
Share Paper
